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Involvement of avb5 Integrin in the Establishment of
Autocrine TGF-b Signaling in Dermal Fibroblasts
Derived from Localized Scleroderma
Yoshihide Asano1, Hironobu Ihn1,2, Masatoshi Jinnin1, Yoshihiro Mimura1 and Kunihiko Tamaki1
Localized scleroderma (LSc) is a connective tissue disorder limited to skin and subcutaneous tissue, which may
share pathogenic processes with systemic sclerosis (SSc). We previously demonstrated that upregulated
expression of integrin avb5 might contribute to autocrine TGF-b signaling in SSc fibroblasts. Based on these
data, we presently focused on avb5 and assessed its involvement in pathogenesis of LSc. We initially
demonstrated that LSc fibroblasts might be activated by the stimulation of autocrine TGF-b. Consistent with SSc
fibroblasts, expression levels of avb5 were elevated in LSc fibroblasts in vitro and in vivo. Anti-avb5 antibody
partially reversed expression levels of type I procollagen and MMP-1 and constitutive DNA–Smad3 binding in
LSc fibroblasts. In LSc fibroblasts pretreated with antisense TGF-b1, exogenous latent TGF-b1 stimulation
increased expression of type I procollagen in an avb5-dependent manner. The luciferase activities of TMLC cells,
Mv1Lu cells stably expressing a portion of the plasminogen activator inhibitor 1 promoter, co-cultured with LSc
fibroblasts were significantly elevated compared with those co-cultured with normal fibroblasts and were
significantly reduced in the presence of anti-avb5 antibody. Anti-avb5 antibody reversed the myofibroblastic
features of LSc fibroblasts. These results indicate that upregulated expression of avb5 contributes to autocrine
TGF-b signaling in LSc fibroblasts.
Journal of Investigative Dermatology (2006) 126, 1761–1769. doi:10.1038/sj.jid.5700331; published online 4 May 2006
INTRODUCTION
Localized scleroderma (LSc) is a connective tissue disorder
limited to the skin and subcutaneous tissue, often involving
the muscular tissues beneath the cutaneous lesions. The
absence of Raynaud’s phenomenon, of acrosclerosis, and of
involvement of internal organs differentiates it from systemic
sclerosis (SSc) (Jablonska and Rodnan, 1979). However, the
two diseases may share similar pathogenetic processes, since
abnormal collagen metabolism (Higley et al., 1994; Kubo
et al., 2001; Asano et al., 2004a, b, c; Asano et al., 2005a)
and autoimmunity (Kahaleh, 1993; Takehara and Sato, 2005)
are considered to be fundamental characteristics of both.
Elevated collagen synthesis by skin fibroblasts derived from
involved lesions is one of the common characteristics of the
two conditions and may be closely related to their
pathogenesis.
TGF-b1 is a multifunctional cytokine that regulates the
growth, differentiation, and function of various cell types
(Wahl, 1994). The principal effect of TGF-b1 on mesench-
ymal cells is its stimulation of extracellular matrix deposition.
TGF-b1 has been shown to increase the expression of
collagen types I, III, VI, VII, and X, fibronectin, and proteo-
glycans (LeRoy, 1974; Buckingham et al., 1978; Falanga
et al., 1987; Raghow et al., 1987; Peltonen et al., 1990;
Xu et al., 1991; Rudnicka et al., 1994; Jelaska et al., 1996).
Stimulation of extracellular matrix production by TGF-
b1 is further enhanced by its inhibitory effect on matrix
degradation, decreasing the synthesis of proteases and
increasing levels of protease inhibitors (Massague, 1990).
The involvement of TGF-b in the pathogenesis of dermal
fibrosis in SSc has been well-studied. Since many of the
characteristics of SSc fibroblasts resemble those of healthy
fibroblasts stimulated by TGF-b1 (LeRoy et al., 1989;
Massague, 1990), the dermal fibroblast activation in SSc is
thought to be a result of stimulation by autocrine TGF-b. This
notion is supported by our previous findings that (i) SSc
fibroblasts express elevated levels of TGF-b receptors, and
this correlates with elevated levels of a2(I) collagen mRNA
(Kawakami et al., 1998) and (ii) the blockade of TGF-b
signaling with anti-TGF-b antibodies or TGF-b1 antisense
oligonucleotide (AS-TGF-b1) abolished the increased
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expression of human a2(I) collagen mRNA in SSc fibroblasts
(Ihn et al., 2001).
TGF-b1 is normally secreted as a complex composed of
three proteins, including the bioactive peptide of TGF-b1, a
latency-associated peptide-b1 (LAP-b1), and a latent TGF-b-
binding protein-1. TGF-b1 forms a complex with LAP-b1
noncovalently, which is called the small latent complex
(SLC), and in this configuration TGF-b1 is unable to bind to its
receptors. SLC is joined by a latent TGF-b-binding protein-1,
the N-terminal region of which is covalently crosslinked to
extracellular matrix proteins by transglutaminase, and the
complex of all three proteins is called the large latent
complex (Annes et al., 2003). The constitutive secretion of
latent TGF-b1 by many cell types in culture suggests that
there are extracellular mechanisms to control the activity of
this potent cytokine.
LAP-b1 contains an RGD motif that is recognized by av-
containing integrins, including avb1, avb3, avb5, avb6, and
avb8 (Munger et al., 1998; Munger et al., 1999; Mu et al.,
2002; Ludbrook et al., 2003). Though all of these av-
containing integrins bind to LAP-b1 and have the potential
to modulate the localization and possibly activation of SLC,
only avb6 and avb8, both of which are not expressed in
dermal fibroblasts, have been demonstrated to be able to
activate SLC (Munger et al., 1999; Mu et al., 2002). Though
there have been no reports which indicate the activation of
SLC by other av-containing integrins (avb1, avb3, and avb5),
we previously demonstrated that avb5 is upregulated in SSc
dermal fibroblasts and the transient overexpression of avb5
induces the increased transcriptional activity of human a2(I)
collagen gene in normal dermal fibroblasts (Asano et al.,
2004a). Furthermore, our recent report suggested that the
upregulated expression of avb5 contributes to the establish-
ment of autocrine TGF-b signaling in SSc fibroblasts (Asano
et al., 2005b, Asano et al., 2006).
To clarify the similarity and the difference is a distinctively
important process to further disclose the mechanism of
fibrosis in LSc and SSc. We previously demonstrated that the
expression levels of TGF-b receptors were elevated in LSc
fibroblasts as well as in SSc fibroblasts by immunohisto-
chemistry and in situ hybridization (Kubo et al., 2001). In
spite of the difference in autoimmune abnormalities (Take-
hara and Sato, 2005), these two disorders may share several
aspects of fibrotic processes, including autocrine TGF-b
signaling. The goal of this study is to investigate whether
autocrine TGF-b signaling is involved in the self-activation
system in LSc fibroblasts. In addition, we investigated the
involvement of avb5 in the establishment of autocrine TGF-b
signaling in LSc fibroblasts.
RESULTS
Expression levels of type I procollagen and MMP-1 in LSc
fibroblasts
As an initial experiment, we compared the expression levels
of type I procollagen and MMP-1 between normal and LSc
fibroblasts by immunoblotting. As shown in Figure 1, the
expression levels of type I procollagen protein were
significantly elevated in LSc fibroblasts compared with
normal fibroblasts (4.2-fold, Po0.05). By contrast, the
expression levels of MMP-1 were significantly decreased in
LSc fibroblasts compared with normal fibroblasts (0.07-fold,
Po0.05). These results suggest that the increased synthesis
and the decreased degradation of type I collagen contribute
to the dermal fibrosis in LSc.
LSc fibroblasts may be activated by the stimulation of
autocrine TGF-b. To clarify whether the activation of LSc
fibroblasts is the result of the stimulation by autocrine TGF-b,
we investigated the effect of AS-TGF-b1 on the expression
levels of type I procollagen and MMP-1. As shown in Figure
2a, the treatment of AS-TGF-b1 significantly reduced the
expression levels of type I procollagen protein and increased
the expression levels of MMP-1 protein to a similar extent to
those observed in normal fibroblasts. These results indicate
that LSc fibroblasts may be activated by the stimulation of
autocrine TGF-b1. To further confirm this point, we next
focused on the activation state of TGF-b signaling. In our
previous report, we demonstrated that the phosphorylation
level of Smad3, determined by immunoprecipitation, and the
DNA-binding ability of Smad3, determined by DNA affinity
precipitation, were significantly elevated in SSc fibroblasts
and that the phosphorylation level of Smad3 was completely
correlated with the DNA-binding ability of Smad3 (Asano
et al., 2004c; Asano et al., 2005b). Since DNA affinity
precipitation is highly sensitive to detect the DNA-binding
ability of Smad3, we used this method to determine the
activation state of TGF-b signaling in LSc fibroblasts. As
shown in the upper panel in Figure 2b, the DNA–Smad3
binding was marginal in normal fibroblasts. In contrast, the
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Figure 1. Comparison of the expression levels of type I procollagen and
MMP-1 between normal and LSc fibroblasts. Whole-cell lysates were
analyzed by immunoblotting using anti-type I collagen antibody, anti-MMP-1
antibody, or anti-b-actin antibody. One representative of five independent
experiments is shown (upper panel). The protein levels quantitated by
scanning densitometry and corrected for the level of b-actin in the same
samples are shown relative to those in normal fibroblasts (100 arbitrary units
(AU)) (lower panel). The levels of type I procollagen proteins were defined as
the mean band density of a1(I) and a2(I) procollagen proteins. Data are
expressed as the mean7SD of five independent experiments. *Po0.05 versus
normal fibroblasts. NS: normal skin fibroblasts. LSc: localized scleroderma
fibroblasts.
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constitutive DNA–Smad3 binding was detected in LSc
fibroblasts. These results indicate that TGF-b signaling is
constitutively activated in LSc fibroblasts. Next, we investi-
gated the effect of AS-TGF-b1 on the DNA–Smad3 binding in
LSc fibroblasts. As shown in the middle panel in Figure 2b,
the DNA–Smad3 binding was markedly elevated in normal
fibroblasts treated with TGF-b1 and the treatment of AS-TGF-
b1 showed no effect on the DNA–Smad3 binding in normal
fibroblasts. In contrast, the same treatment almost completely
abolished the DNA–Smad3 binding in LSc fibroblasts. These
results confirmed the notion that LSc fibroblasts may be
activated by the stimulation of autocrine TGF-b.
Expression levels of av and b5 subunit proteins in cultured
normal and LSc fibroblasts
To investigate whether avb5 is involved in the establishment
of the autocrine TGF-b signaling in LSc fibroblasts, we
initially compared the expression levels of av and b5 subunit
proteins between cultured normal and LSc fibroblasts by
immunoblotting. As shown in Figure 3a, the expression levels
of av and b5 subunit proteins were significantly higher in LSc
fibroblasts than normal fibroblasts (2.5- and 4.5-fold increase,
respectively).
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Figure 2. LSc fibroblasts may be activated by the stimulation of autocrine
TGF-b. (a) Cells were treated with the indicated reagent for 48 hours. Whole-
cell lysates were analyzed by immunoblotting using indicated antibodies.
One representative of five independent experiments is shown (upper panel).
The protein levels quantitated by scanning densitometry and corrected for the
level of b-actin in the same samples are shown relative to those in normal
fibroblasts (100 AU) (lower panel). (b) Cells were treated with TGF-b1
antisense oligonucleotide (AS-TGF-b1) or TGF-b1 sense oligonucleotide
(S-TGF-b1) for 48 hours. In some experiments, cells were treated with TGF-b1
for the last 3 hours. Nuclear extracts were incubated with biotin-labeled
oligonucleotides. Proteins bound to these nucleotides were isolated with
streptavidin-agarose beads, and Smad3 was detected by immunoblotting.
One representative of five independent experiments is shown in the upper
and middle panels. In the lower panels, relative Smad3 levels quantitated by
scanning densitometry are shown relative to those in normal fibroblasts
treated with 10mM of S-TGF-b1 and 2 ng/ml of TGF-b1 (100 AU). The mean
and SD from 5 separate experiments are shown. *Po0.05 versus normal
fibroblasts treated with S-TGF-b1. **Po0.05 versus LSc fibroblasts treated
with S-TGF-b1.
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Figure 3. Comparison of the expression levels of avb5 between normal and
LSc fibroblasts. (a) Whole-cell lysates were analyzed by immunoblotting
using indicated antibodies. One representative of five independent
experiments is shown (upper panel). The protein levels quantitated by
scanning densitometry and corrected for the level of b-actin in the same
samples are shown relative to those in normal fibroblasts (100 AU) (lower
panel). Data are expressed as the mean7SD of five independent experiments.
*Po0.05 versus normal fibroblasts. (b) Cell surface proteins were labeled with
biotin and cell lysates were immunoprecipitated using anti-b5 antibody. One
representative of five independent experiments is shown. (c) Paraffin sections
of normal and LSc dermal tissue were subjected to immunohistochemical
analysis with anti-avb5 antibody. The immunoreactivity was visualized by
diaminobenzidine. The sections were counterstained with hematoxylin.
Original magnification,  200.
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Expression levels of avb5 on the surface of cultured normal and
LSc fibroblasts
To function as active receptors, integrins have to be present
on the cell surface as dimers. Therefore, we next determined
the cell surface levels of avb5 in normal and LSc fibroblasts.
To this end, cell surface proteins were labeled with biotins
and immunoprecipitation was performed using anti-b5 anti-
body. As shown in Figure 3b, cell surface levels of avb5 were
markedly elevated in LSc fibroblasts compared with normal
fibroblasts. These bands were confirmed to be av or b5 by a
reprobing analysis using anti-av or b5 antibodies (data not
shown).
Distribution of avb5 protein in normal and LSc dermal sections
To investigate the distribution of avb5 protein in vivo,
immunohistochemical staining was performed using dermal
section derived from four LSc patients and four normal
controls. Representative results are shown in Figure 3c.
Regarding the epidermis, blood vessels, and smooth muscles,
there was no difference in immunoreactivity for the anti-avb5
antibody between normal and LSc dermal sections. The
expression of the avb5 protein was strong in the blood vessels
and smooth muscles, and weak in the epidermis. However,
the spindle-shaped cells, especially those between thickened
collagen bundles in the middle and deep dermis, demon-
strated strong immunoreactivity for the avb5 protein in LSc
dermal sections, whereas those in normal skin sections were
weakly stained. These results were consistent with the results
for cultured fibroblasts described above. Unexpectedly, the
epitope of the avb5 protein was also observed scattered
between thickened collagen bundles in all LSc dermal
sections.
The treatment of anti-avb5 antibody partially reversed the
expression levels of type I procollagen and MMP-1 by
reducing the constitutive DNA–Smad3 binding in LSc
fibroblasts. We next investigated the effects of anti-avb5
antibody on the expression levels of type I procollagen and
MMP-1. As shown in Figure 4a, this antibody partially, but
significantly, reversed the expression levels of type I pro-
collagen and MMP-1 in LSc fibroblasts. We also investi-
gated the effect of anti-avb5 antibody on the DNA–Smad3
binding levels in LSc fibroblasts. As shown in Figure 4b,
the pretreatment of anti-avb5 antibody did not affect the
DNA–Smad3 binding levels in normal fibroblasts either
treated or untreated with TGF-b1. In contrast, the treatment
of anti-avb5 antibody partially, but significantly, reduced the
DNA–Smad3 binding levels in LSc fibroblasts. These results
indicate that the upregulation of avb5 may be involved in the
activation of TGF-b signaling in LSc fibroblasts.
Exogenous SLC stimulation induces the expression of type I
procollagen in LSc fibroblasts
Next, we compared the ability to activate SLC between
normal and LSc fibroblasts. To this end, we investigated the
effect of exogenous SLC stimulation on the expression levels
of type I procollagen protein. To suppress the endogenous
TGF-b1 production, cells were pretreated with 10mM of
AS-TGF-b1 for 48 hours prior to the stimulation by active
TGF-b1 or SLC. As shown in the upper panels of Figure 5a,
AS-TGF-b1 significantly decreased the expression levels of
type I procollagen protein in LSc fibroblasts to levels similar
to those in normal fibroblasts. Exogenous active TGF-b1
stimulation showed a significant increase in the expression
levels of type I procollagen protein in normal and LSc
fibroblasts pretreated with AS-TGF-b1. In contrast, exogenous
SLC stimulation showed a significant increase in the
expression levels of type I procollagen protein in LSc
fibroblasts treated with AS-TGF-b1, while the same treatment
revealed no significant effect in normal fibroblasts treated
with AS-TGF-b1. Furthermore, as shown in the lower panels
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Figure 4. Anti-avb5 antibody partially reverses the expression levels of type I
procollagen and MMP-1 and the DNA–Smad3 binding levels in LSc
fibroblasts. (a) Cells were treated with the indicated reagents for 48 hours.
Whole-cell lysates were analyzed by immunoblotting using indicated
antibodies. One representative of five independent experiments is shown
(upper panel). The protein levels quantitated by scanning densitometry and
corrected for the level of b-actin in the same samples are shown relative to
those in normal fibroblasts treated with preimmune IgG (100 AU) (lower
panel). (b) Cells were treated with the indicated antibodies for 48 hours. In
some experiments, cells were treated with TGF-b1 for the last 3 hours.
Nuclear extracts were incubated with biotin-labeled oligonucleotides.
Proteins bound to these nucleotides were isolated with streptavidin-agarose
beads, and Smad3 was detected by immunoblotting. One representative of
five independent experiments is shown in the upper panels. In the lower
panels, relative Smad3 levels quantitated by scanning densitometry are shown
relative to those in normal fibroblasts treated with preimmune IgG and
TGF-b1 (100 AU). The mean and SD from five separate experiments are
shown. *Po0.05 versus normal fibroblasts treated with preimmune IgG.
**Po0.05 versus LSc fibroblasts treated with preimmune IgG.
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of Figure 5a, this effect of SLC in LSc fibroblasts was
significantly reduced by the pretreatment of anti-avb5 anti-
body. These results suggest that the upregulated expression of
avb5 contributes to the SLC activation in LSc fibroblasts.
Latent TGF-b is activated on the cell surface of LSc fibroblasts
through avb5-dependent pathway
We next investigated the localization of active TGF-b in
normal and LSc fibroblasts by coculture assay. In this assay,
normal or LSc fibroblasts were cocultured with TMLC cells
(Figure 5b). Since the luciferase activity of TMLC cells is
hypersensitive to the stimulation of TGF-b, this assay can
determine the localization of active TGF-b in normal and LSc
fibroblasts. In the situation that active TGF-b is localized on
the cell surface of fibroblasts, the luciferase activity of TMLC
cells cocultured in the presence of cell contact will be
significantly elevated compared with that cocultured in the
absence of cell contact. By contrast, in the situation that
active TGF-b is freely diffusible in cell culture medium, there
will be no significant difference in the luciferase activity
between TMLC cells cocultured in the presence of cell
contact and those cocultured in the absence of cell contact.
The luciferase activity was significantly elevated in TMLC
cells cocultured with LSc fibroblasts compared with those
with normal fibroblasts (about 5.5-fold increase, Po0.05).
This increase was significantly reduced by anti-avb5 antibody
(about 50% reduction) and almost completely abolished by
anti-TGF-b antibody, while preimmune mouse or rabbit IgG
showed no effect. We also carried out coculture assays with
inserts to separate TMLC cells and normal or LSc fibroblasts
while allowing soluble molecules to pass. In the absence of
contact, LSc fibroblasts showed no significant induction of
luciferase activity. These results indicate that SLC is activated
on the cell surface of LSc fibroblasts and suggest that this
activation process was partially attributed to avb5-dependent
pathway.
Blockade of avb5 reverses the myofibroblastic phenotype of LSc
fibroblasts
Finally, we performed immunofluorescence using anti-a-
smooth muscle actin (SMA) antibody to determine the effect
of anti-avb5 antibody on the expression levels of a-SMA and
the morphology of cells (Figure 6). In LSc fibroblasts, about
80% of cells showed the morphological changes of cellular
hypertrophy and well-formed a-SMA fibers, which are
characteristics of myofibroblasts. However, after the treat-
ment of anti-avb5 antibody, the percentage of cells with these
features was reduced to about 30%. In contrast, in normal
fibroblasts, cells with these features were less than 5% in the
presence or absence of functional blocking antibody. These
results indicate that anti-avb5 antibody reverses the myofi-
broblastic phenotype of LSc fibroblasts.
DISCUSSION
This study was undertaken to clarify the mechanism of the
activation process in LSc fibroblasts. We initially demon-
strated the following three evidences: (i) The expression
levels of type I procollagen protein are elevated and those of
MMP-1 protein were decreased in LSc fibroblasts. (ii)
Constitutive DNA–Smad3 binding is observed in LSc fibro-
blasts. (iii) The treatment of AS-TGF-b1 reverses the expres-
sion levels of type I procollagen protein and MMP-1 protein
in LSc fibroblasts to levels similar to those observed in normal
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Figure 5. Endogenous latent TGF-b is activated on the cell surface of LSc
fibroblasts in the avb5-dependent manner. (a) Cells treated with AS-TGF-b1
(10mM, for 72 h) were stimulated with indicated reagents (TGF-b1 or SLC) for
the last 24 hours. In some experiments, SLC stimulation was performed in the
presence of anti-avb5 antibody or preimmune IgG. Whole-cell lysates were
analyzed by immunoblotting using indicated antibodies. One representative
of five independent experiments is shown (upper and middle panels). The
protein levels quantitated by scanning densitometry and corrected for the
level of b-actin in the same samples are shown relative to those in LSc
fibroblasts treated with AS-TGF-b1 (100 AU) (lower panel). Data are
expressed as the mean7SD of five independent experiments. *Po0.05 versus
LSc fibroblasts treated with AS-TGF-b1. **Po0.05 versus LSc fibroblasts
treated with AS-TGF-b1, SLC, and preimmune IgG. (b) Either normal or LSc
fibroblasts were mixed with TMLC cells at a ratio of 1:1 and cocultured in
confluence. In experiments without cell–cell contact, either normal or LSc
fibroblasts were cocultured with TMLC cells separately by using inserts. After
24-hour incubation, the luciferase activities were determined. In some
experiments, assays were performed in the presence of anti-avb5 antibody
(anti-avb5, 10 mg/ml), preimmune mouse IgG (M-IgG, 10 mg/ml), anti-TGF-b
antibody (anti-TGF-b, 10mg/ml), or preimmune rabbit IgG (R-IgG, 10 mg/ml).
Values represent the luciferase activity relative to that of TMLC cells
cocultured with normal fibroblasts in the absence of contact (100 AU). The
mean and SD from five separate experiments are shown. *Po0.05 versus
normal fibroblasts under the same condition. **Po0.05 versus LSc fibroblasts
treated with preimmune mouse IgG (a control against anti-avb5 antibody) or
preimmune rabbit IgG (a control against anti-TGF-b antibody).
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fibroblasts and almost completely diminishes the constitutive
DNA–Smad3 binding in LSc fibroblasts. These results indicate
that LSc fibroblasts may be activated by the stimulation of
autocrine TGF-b. In addition, the evidence that blockade of
endogenous TGF-b1 did not completely reverse the myo-
fibroblastic phenotype of LSc fibroblasts suggests that there
are other fibrogenic cytokines in addition to TGF-b1 that
participate in the fibrogenesis and generation of the
myofibroblast phenotype in those cells. Although the detailed
mechanism of autocrine TGF-b signaling remains to be
clarified, Kawakami et al (1998) previously demonstrated that
the upregulated expression of TGF-b receptors could estab-
lish the autocrine TGF-b signaling in dermal fibroblasts. Since
the expression levels of TGF-b receptors are elevated in LSc
fibroblasts in vivo (Kubo et al., 2001), such abnormalities
may contribute to the establishment of autocrine TGF-b
signaling in LSc fibroblasts. To further elucidate the mechan-
ism of dermal fibroblast activation in LSc, we next focused on
avb5, which is recently demonstrated to be involved in the
establishment of autocrine TGF-b signaling in SSc fibroblasts
(Asano et al., 2005b), and verified the following three
evidences: (i) The expression levels of avb5 are elevated in
LSc fibroblasts in vivo and in vitro. (ii) Anti-avb5 antibody
partially, but significantly, reverses the expression levels of
type I procollagen protein and MMP-1 protein and reduces
the constitutive DNA–Smad3 binding in LSc fibroblasts. (iii)
SLC is activated on the cell surface of LSc fibroblasts through
avb5-dependent pathway. These results indicate that the
upregulated expression of avb5 may contribute to the
establishment of autocrine TGF-b signaling in LSc fibroblasts
through activating endogenous latent TGF-b1. To our knowl-
edge, this is the first report which demonstrates the similarity
in the self-activation system between SSc and LSc fibroblasts.
Previous reports demonstrated that all of av-containing
integrins bind to LAP-b1 and have the potential to modulate
the localization and possibly activation of SLC (Munger et al.,
1998; Munger et al., 1999; Mu et al., 2002; Ludbrook et al.,
2003). Taken together with this notion, the present findings
indicate that avb5 may recruit and activate SLC on the cell
surface of LSc fibroblasts. To our best knowledge, the
following two mechanisms have been proposed in the
activation process of SLC: (i) the proteolysis of LAP and (ii)
the conformational change of LAP. The former mechanism is
attributed to proteases such as plasmin, metalloproteases,
aspartic proteases, cysteine proteases, and serine proteases,
resulting in the release of active TGF-b from LAP (Lyons et al.,
1990; Schultz-Cherry et al., 1994; Munger et al., 1998).
The latter mechanism is well-studied in thrombospondin-1
and avb6. SLC binds to thrombospondin-1 through the
N-terminus of LAP and such interaction induces a conforma-
tional change and a subsequent activation of SLC, although
the active TGF-b molecules remain bound to thrombospon-
din-1 (Schultz-Cherry et al., 1994; Crawford et al., 1998). SLC
also interacts with avb6 through the C-terminus of LAP, but
such interaction is not sufficient for its activation. Following
the binding, avb6 requires the interaction with actin
cytoskeleton to activate bound SLC (Munger et al., 1999).
Since the previous finding that only b5 has a cytoplasmic
domain highly homologous to those of b6 subunits among
b1, b3, b5, and b8, which can interact with av subunit
(Yla¨nne, 1998), avb5 may activate SLC by a nonproteolytic
pathway. Further studies are required to disclose this point.
In general, the biological effect of cytokines, including
TGF-b1, is mainly determined by the occurrence of
cytokine–receptor interaction, which is modulated by the
concentration and the activity of cytokines and/or their
receptors. Therefore, the concentration and/or the activity of
TGF-b1 as well as the expression levels of its receptors are
important aspects in the pathogenesis of SSc and LSc. Since
we previously demonstrated that the expression levels of
TGF-b receptors were elevated in SSc and LSc fibroblasts
(Kawakami et al., 1998; Ihn et al., 2001; Kubo et al., 2001;
Asano et al., 2004a), our next interest had been focused on
the molecules which recruit and/or activate latent TGF-b1 in
the pericellular region. In this study, we demonstrated that
one of the molecules that mediate this process in LSc may be
avb5 as well as in SSc and this finding strongly supports the
further understanding of the establishment of autocrine TGF-b
signaling in LSc fibroblasts.
Previous reports demonstrated that TGF-b1-null animals
developed massive autoimmune inflammation affecting
multiple organs because TGF-b is one of the major regulators
of immune system (Shull et al., 1992). In addition, expression
of kinase-deficient TbRII selectively in fibroblasts leads to
paradoxical ligand-dependent activation of TGF-b signaling
and causes skin and lung fibrosis in transgenic mice (Denton
et al., 2003). These previous data suggest that TGF-b
receptors cannot be a target for developing the treatment of
fibrotic disorders. In such a situation, the molecules that can
modulate the activation state of latent TGF-b and/or its
interaction with TGF-b receptors, such as avb5, can be the
next new target for the treatment of fibrotic disorders.
The present observation that the blockade of avb5 reverses
the myofibroblastic phenotype in LSc fibroblasts strongly
Preimmune IgG
NS
LSc
Anti-v5 antibody
Figure 6. Effect of blocking antibodies against avb5 on the morphological
features in normal and LSc fibroblasts. Cells were treated with indicated
antibodies for 48 hours. Cells were stained with anti-a-smooth muscle actin
antibody, washed, and incubated with FITC-conjugated rabbit anti-mouse
IgG (green). The nuclei were counterstained with DAPI (blue).
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supports this notion. A previous study demonstrated that b5-
knockout mice develop, grow, and reproduce normally and
show no abnormality in wound healing and adenovirus
infection, which are the major biological processes avb5
participates in (Huang et al., 2000). These previous observa-
tions suggest that most roles of avb5 can be compensated for
by other avb5-independent pathways. Taken together, this
functional redundancy in avb5 makes the pharmacological
interference of avb5 functions a promising approach to the
treatment of LSc.
In summary, this study demonstrated that LSc fibroblasts
might be activated by the stimulation of autocrine TGF-b and
the upregulated expression of avb5 might be implicated in
this process. These present findings reinforce the notion that
SSc and LSc share the pathogenesis of dermal fibrosis.
Although in vivo studies using animal models are required in
the future, the present data suggest that this integrin can be a
promising target in developing the treatment of fibrotic
disorders, especially SSc and LSc.
MATERIALS AND METHODS
Reagents
Recombinant human TGF-b1 and SLC were obtained from R&D
systems (Minneapolis, MN). Antibodies for b-actin and a-SMA were
purchased from Sigma (St Louis, MO). Antibodies for b5 subunit
(E-19) and av subunit (Q-20) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Functional blocking antibodies
against avb5 (P1F6) and antibody against MMP-1 were purchased
from Chemicon (San Francisco, CA). Anti-Smad2/3 antibody
(S66220) was obtained from Transduction laboratories
(Lexington, KY).
Cell cultures
Human dermal fibroblasts were obtained by skin biopsy from the
affected areas, which developed within 1 year, of four patients with
LSc. All of the patients were diagnosed by clinical appearance and
histologic findings, and none of them had any other collagen
disease, including SSc. Four patients were classified into the
following three subgroups: one patient with generalized morphea
(sex and biopsy site; female, right thigh), one with linear scleroderma
(female, right upper arm), and two with morphea (female, abdomen;
male, abdomen) as described previously (Sato et al., 1994). Control
fibroblasts were obtained by skin biopsy from four healthy donors.
Ideal control in this study should be the adjacent skin, not the totally
different individuals. However, skin biopsies from uninvolved areas
were not obtained in those patients. Informed consent was obtained
from all subjects. Control donors were matched with each LSc
patient for age, sex, and biopsy site, and control and patient samples
were processed in parallel. Primary explant cultures were estab-
lished in 25 cm2 culture flasks in minimum essential medium (MEM)
with 10% FCS, 2 mM L-glutamine, and 50 mg/ml of amphotericin.
Fibroblast cultures were maintained as monolayers at 371C in 95%
air, 5% CO2, and studied between the third and sixth subpassages.
TMLC cells, which were kindly provided by Dr Daniel B. Rifkin,
were cultured in MEM with 10% FCS until assayed. In all
experiments, cells were cultured in serum-free medium for at least
24 hours before the addition of any reagents. All described studies
were approved by the Graduate School of Medicine, University of
Tokyo and The University of Tokyo Hospital. This study was
conducted according to the Declaration of Helsinki principles.
Immunoblotting
Protein extracts were subjected to SDS-PAGE and transferred to
nitrocellulose membranes. Membranes were incubated overnight
with primary antibody, washed, and incubated for 1 hour with
secondary antibody. After washing, visualization was performed by
enhanced chemiluminescence (Amersham Pharmacia Biotech,
Buckinghamshire, UK).
Biotinylation and immunoprecipitation
Confluent quiescent cells were incubated with membrane-imper-
meant NHS-LC-biotin (Pierce, Rockford, IL) dissolved at 0.5 mg/ml.
in phosphate-buffered saline (PBS) at 41C for 30 minutes. Immuno-
precipitation was performed using whole-cell lysates. Each immu-
noprecipitate was subjected to SDS-PAGE, and Western blots were
prepared. The blots were probed with streptavidin coupled to
horseradish peroxidase and visualized by enhanced chemilumines-
cence.
Immunohistochemical stainings
Immunohistochemical staining of paraffin-embedded sections was
performed using a Vecstain ABC kit (Vector Laboratories, Burlin-
game, CA) according to the manufacturer’s instructions as described
previously (Asano et al., 2004b). 4-mm thick sections were mounted
on silane-coated slides, then deparaffinized with xylene and
rehydrated through a graded series of solutions of ethyl alcohol
and PBS. The sections were then incubated with antibody against
avb5 diluted 100-fold in PBS overnight at 41C. The immunoreactivity
was visualized using diaminobenzidine. The sections were then
counterstained with hematoxylin.
DNA affinity precipitation
Two oligonucleotides containing biotin on the 50-nucleotide of the
sense strand were prepared as described previously (Yagi et al.,
2002). Poly(dI-dC) competitor (5 mg) was incubated with 500 mg of
nuclear protein for 30 minutes at 41C, followed by 1 hour incubation
with 500 pmol of each oligonucleotide. Then, 65 ml of streptavidin-
agarose (Sigma) was added to the reaction and incubated at 41C for
overnight. The precipitated proteins were subjected to immunoblot-
ting with anti-Smad2/3 antibody. The specific binding of Smad3 with
3CAGA oligo was confirmed by the experiments using 3CAGA-
M oligo. The binding of Smad3 with 3CAGA-M oligo was not
observed in the presence or absence of TGF-b1 (data not shown), as
described previously (Asano et al., 2004c).
TGF-b bioassay
To determine the TGF-b activation, TMLC cells, mink lung epithelial
reporter cells stably expressing a portion of the plasminogen
activator inhibitor 1 promoter (Abe et al., 1994), were cocultured
with test cells as described previously (Asano et al., 2005b, c; Asano
et al., 2006). TMLC cells are highly responsive to TGF-b and produce
a very low background of TGF-b activation. TMLC cells can thus be
used in coculture with other cell lines or cell-free fractions to test for
the presence of active TGF-b using luminescence as a readout.
TMLC and test cells were mixed in a ratio of 1:1 and suspended at
1 106 cells/ml in MEM containing 10% FBS. These cells were
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plated at 200ml/well in 12-well plates and allowed to attach for
1 hour. The medium was replaced with 200 ml/well of new serum-
free medium and cultured for 24 hour. Cell lysates were prepared
using the Reporter Lysis Buffer (Promega, Madison, WI) and the
luciferase activity was determined using the Promega luciferase
assay system. Similar cocultures were done in 24-well plates with
inserts designed for attachment-dependent cell culture (Millicell-PCF
3mm filter, Millipore, Bedford, MA), but 1.5 105 of TMLC and test
cells were added to the upper or lower chambers. In some
experiments, cocultures were performed in the presence of anti-
avb5 antibody, preimmune mouse IgG, anti-TGF-b antibody, or
preimmune rabbit IgG.
Immunofluorescence
Cells grown in four-well LAB TEK chambers (Nunc, Naperville, IL)
were treated with 10 mg/ml of anti-avb5 antibody (P1F6) or
preimmune mouse IgG for 48 hours. Then, cells were fixed with
3.7% formaldehyde, permeabilized with 0.5% Triton X-100 in PBS,
and blocked with 10% FCS in PBS containing 0.5% Triton X-100.
Cells were stained with anti-a-SMA antibody, washed, and
incubated with FITC-conjugated rabbit anti-mouse IgG (Sigma).
Myofibroblast was defined as the cell with features such as cellular
hypertrophy and well-formed a-SMA fibers. To determine the
percentage of cells which differentiate into myofibroblasts, hundred
cells per each cell strain were examined microscopically.
Statistical analysis
Data presented as bar graphs are the means7SD of at least five
independent experiments. Statistical analysis was performed using
the Mann–Whitney U-test (Po0.05 was considered significant).
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